HOME >> MEDICINE >> NEWS
BioNumerik Reports Preclinical Antitumor Data On Two Novel Supercomputer Engineered Anticancer Agents At 89th Annual AACR Conference

tives. These results also demonstrate the ability of BioNumerik's Karenitecins to bypass common drug resistance mechanisms (MDR, MRP & LRP) to which many other camptothecins appear to be susceptible. Because its compounds are lipophilic, BioNumerik believes its Karenitecins will have enhanced tissue penetration, drug delivery and bioavailability compared to water soluble camptothecins.

Camptothecins, described as Topoisomerase I inhibitors, represent some of the most active anticancer drugs in existence. Due to formulation problems, however, the great majority of camptothecins in development or on the market have been made water soluble to allow easier drug dissolution and administration. BioNumerik believes that this approach may limit the utility of these drugs and the Company has developed a new generation of proprietary highly lipophilic (fat loving) camptothecins, known as Karentitecins, that have been designed to overcome problems that exist with camptothecin and the current camptothecin derivatives.

Using its mechanism-based approach, BioNumerik used its Cray supercomputers to construct a detailed computational model involving human Topoisomerase I and DNA in order to understand and more precisely target the key interactions between camptothecin-Topo I/DNA. BioNumerik used this information to guide and complement the discovery and optimization of novel compounds for laboratory synthesis and preclinical testing.

In a presentation titled "BNP7787: Administration In Vivo Results in Increased Therapeutic Index and Toxicity Reduction of Platinum Drugs", BioNumerik also presented data on its proprietary agent BNP7787, a novel water soluble disulfide that was engineered to increase the therapeutic index of cisplatin and carboplatin, two widely used anticancer drugs.

Although platinum chemotherapy is widespread, formulations of cisplatin and carboplatin have a major risk of kidney toxicity (cisplatin), nausea and vomiting, bone marrow suppressio
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
212-696-4455 x. 205
Noonan/Russo Communications
30-Mar-1998


Page: 1 2 3 4 5

Related medicine news :

1. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
2. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
3. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
4. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
5. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
6. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
7. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
8. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
9. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
10. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
11. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports

Post Your Comments:
(Date:11/26/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... understand what they,re saying, a new study suggests they are ... way. Past research has shown that dogs respond to ... and the emotional tone, said study author Victoria Ratcliffe. ... canine brain, according to Ratcliffe, a Ph.D. candidate at the ...
(Date:11/26/2014)... Steven Reinberg HealthDay Reporter ... adults are smoking cigarettes than ever, health officials said. ... about 21 percent in 2005 to 18 percent in 2013. ... million to 42.1 million, despite the increasing population, according to ... However,"we still have a long way to go, and ...
(Date:11/26/2014)... 2014 The Maryland Economic Development ... tenth annual MEDA Awards, which, sponsored by Miles ... Maryland. “The MEDA Awards recognize the individuals, programs ... state. We encourage our members to nominate the ... positive economic impact in the state of Maryland,” ...
(Date:11/26/2014)... November 26, 2014 Increasing demand ... include image guided surgeries has paved way for ... Rising incidence of various types of cancers and ... increase in demand for these owing to their ... contrast media injectors market can also be attributed ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 German scientists ... materials science can cause mesothelioma that looks and acts ... a new article on the research. Click here ... Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover ... While all of the rats eventually developed mesothelioma ...
Breaking Medicine News(10 mins):Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 2Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 3Health News:Maryland Economic Development Association Seeking Submissions for 2015 Awards 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... Pa. , Nov. 26, 2014 ... to the development of innovative transdermal synthetic cannabinoid treatments, ... Piper Jaffray 26th Annual Healthcare Conference 2014. The conference ... New York Palace in New York ... will present at 4:50 pm on Tuesday, December 2. ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
Cached News: